GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » ROIC %

LTR Pharma (ASX:LTP) ROIC % : -439.14% (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. LTR Pharma's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2023 was -439.14%.

As of today (2024-05-09), LTR Pharma's WACC % is 10.05%. LTR Pharma's ROIC % is -439.14% (calculated using TTM income statement data). LTR Pharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.


LTR Pharma ROIC % Historical Data

The historical data trend for LTR Pharma's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma ROIC % Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
ROIC %
-3.92 -197.12 -439.14

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
ROIC % -3.92 -197.12 -439.14

Competitive Comparison of LTR Pharma's ROIC %

For the Biotechnology subindustry, LTR Pharma's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LTR Pharma's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's ROIC % distribution charts can be found below:

* The bar in red indicates where LTR Pharma's ROIC % falls into.



LTR Pharma ROIC % Calculation

LTR Pharma's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Jun. 2023 is calculated as:

ROIC % (A: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Jun. 2022 ) + Invested Capital (A: Jun. 2023 ))/ count )
=-1.436 * ( 1 - 0% )/( (0.3 + 0.354)/ 2 )
=-1.436/0.327
=-439.14 %

where

LTR Pharma's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2023 is calculated as:

ROIC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2022 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-1.436 * ( 1 - 0% )/( (0.3 + 0.354)/ 2 )
=-1.436/0.327
=-439.14 %

where

Note: The Operating Income data used here is one times the annual (Jun. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LTR Pharma  (ASX:LTP) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, LTR Pharma's WACC % is 10.05%. LTR Pharma's ROIC % is -439.14% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


LTR Pharma ROIC % Related Terms

Thank you for viewing the detailed overview of LTR Pharma's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


LTR Pharma (ASX:LTP) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines